Cargando…
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
Peritoneal metastases from invasive lobular carcinoma (ILC) of breast are uncommon and usually related to poor prognosis due to difficulty of detection in clinical practice and drug resistance. Therefore, recognizing the entities of peritoneal metastases of ILC and the potential mechanism of drug re...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531720/ https://www.ncbi.nlm.nih.gov/pubmed/34690920 http://dx.doi.org/10.3389/fendo.2021.659537 |
_version_ | 1784586922900848640 |
---|---|
author | Gao, Hong-Fei Zhang, Jun-Sheng Zhang, Qiang-Zu Zhu, Teng Yang, Ci-Qiu Zhang, Liu-Lu Yang, Mei Ji, Fei Li, Jie-Qing Cheng, Min-Yi Niu, Gang Wang, Kun |
author_facet | Gao, Hong-Fei Zhang, Jun-Sheng Zhang, Qiang-Zu Zhu, Teng Yang, Ci-Qiu Zhang, Liu-Lu Yang, Mei Ji, Fei Li, Jie-Qing Cheng, Min-Yi Niu, Gang Wang, Kun |
author_sort | Gao, Hong-Fei |
collection | PubMed |
description | Peritoneal metastases from invasive lobular carcinoma (ILC) of breast are uncommon and usually related to poor prognosis due to difficulty of detection in clinical practice and drug resistance. Therefore, recognizing the entities of peritoneal metastases of ILC and the potential mechanism of drug resistance is of great significance for early detection and providing accurate management. We herein report a case of a 60-year-old female who presented with nausea and vomiting as the first manifestation after treated with abemaciclib (a CDK4/6 inhibitor) plus fulvestrant for 23 months due to bone metastasis of ILC. Exploratory laparotomy found multiple nodules in the peritoneum and omentum, and immunohistochemistry confirmed that the peritoneal metastatic lesions were consistent with ILC. Palliative therapy was initiated, but the patient died two months later due to disease progression with malignant ascites. Whole exome sequencing (WES) was used to detect the tumor samples and showed the peritoneal metastatic lesions had acquired ESR1 and PI3KCA mutations, potentially explaining the mechanism of endocrine therapy resistance. We argue that early diagnosis of peritoneal metastasis from breast cancer is crucial for prompt and adequate treatment and WES might be an effective supplementary technique for detection of potential gene mutations and providing accurate treatment for metastatic breast cancer patients. |
format | Online Article Text |
id | pubmed-8531720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85317202021-10-23 Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature Gao, Hong-Fei Zhang, Jun-Sheng Zhang, Qiang-Zu Zhu, Teng Yang, Ci-Qiu Zhang, Liu-Lu Yang, Mei Ji, Fei Li, Jie-Qing Cheng, Min-Yi Niu, Gang Wang, Kun Front Endocrinol (Lausanne) Endocrinology Peritoneal metastases from invasive lobular carcinoma (ILC) of breast are uncommon and usually related to poor prognosis due to difficulty of detection in clinical practice and drug resistance. Therefore, recognizing the entities of peritoneal metastases of ILC and the potential mechanism of drug resistance is of great significance for early detection and providing accurate management. We herein report a case of a 60-year-old female who presented with nausea and vomiting as the first manifestation after treated with abemaciclib (a CDK4/6 inhibitor) plus fulvestrant for 23 months due to bone metastasis of ILC. Exploratory laparotomy found multiple nodules in the peritoneum and omentum, and immunohistochemistry confirmed that the peritoneal metastatic lesions were consistent with ILC. Palliative therapy was initiated, but the patient died two months later due to disease progression with malignant ascites. Whole exome sequencing (WES) was used to detect the tumor samples and showed the peritoneal metastatic lesions had acquired ESR1 and PI3KCA mutations, potentially explaining the mechanism of endocrine therapy resistance. We argue that early diagnosis of peritoneal metastasis from breast cancer is crucial for prompt and adequate treatment and WES might be an effective supplementary technique for detection of potential gene mutations and providing accurate treatment for metastatic breast cancer patients. Frontiers Media S.A. 2021-10-08 /pmc/articles/PMC8531720/ /pubmed/34690920 http://dx.doi.org/10.3389/fendo.2021.659537 Text en Copyright © 2021 Gao, Zhang, Zhang, Zhu, Yang, Zhang, Yang, Ji, Li, Cheng, Niu and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Gao, Hong-Fei Zhang, Jun-Sheng Zhang, Qiang-Zu Zhu, Teng Yang, Ci-Qiu Zhang, Liu-Lu Yang, Mei Ji, Fei Li, Jie-Qing Cheng, Min-Yi Niu, Gang Wang, Kun Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature |
title | Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature |
title_full | Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature |
title_fullStr | Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature |
title_full_unstemmed | Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature |
title_short | Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature |
title_sort | peritoneal metastasis after treated with abemaciclib plus fulvestrant for metastatic invasive lobular breast cancer: a case report and review of the literature |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531720/ https://www.ncbi.nlm.nih.gov/pubmed/34690920 http://dx.doi.org/10.3389/fendo.2021.659537 |
work_keys_str_mv | AT gaohongfei peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT zhangjunsheng peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT zhangqiangzu peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT zhuteng peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT yangciqiu peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT zhangliulu peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT yangmei peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT jifei peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT lijieqing peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT chengminyi peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT niugang peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature AT wangkun peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature |